Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.4K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.6K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
991

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generalised absence seizures in Cavalier King Charles Spaniels presenting with paroxysms: eight cases (2016-2025).

The Journal of small animal practice·2026
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Perceived Masticatory Function and Mortality: A Causal Study.

Journal of dental research·2025
Same author

7 Tesla MRI in Multiple Sclerosis: Insights From Its Use in Clinical Routine.

European journal of neurology·2025
Same author

Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.

European journal of cancer (Oxford, England : 1990)·2025

Related Experiment Video

Updated: Apr 16, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

[New therapeutic options in multiple sclerosis].

A Salmen, A Chan

    Fortschritte Der Neurologie-Psychiatrie
    |March 21, 2015
    PubMed
    Summary
    This summary is machine-generated.

    New treatments for multiple sclerosis (MS) offer more options, especially for relapsing-remitting MS. Treatment decisions now balance drug efficacy, safety, and individual patient needs for better outcomes.

    More Related Videos

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.2K
    Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
    09:46

    Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

    Published on: September 21, 2021

    5.4K

    Related Experiment Videos

    Last Updated: Apr 16, 2026

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    13.0K
    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.2K
    Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
    09:46

    Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

    Published on: September 21, 2021

    5.4K

    Area of Science:

    • Neurology
    • Immunology

    Context:

    • Multiple sclerosis (MS) treatment landscape has evolved significantly.
    • Recent advancements include expanded therapeutic options, particularly for relapsing-remitting MS.
    • Revised diagnostic criteria and operationalized disease course definitions impact treatment strategies.

    Purpose:

    • To review current and emerging disease-modifying drugs for multiple sclerosis.
    • To discuss therapeutic decision-making considering disease activity, progression, and individual patient factors.
    • To provide an overview of benefit-risk considerations for MS therapies.

    Summary:

    • The article examines new and established disease-modifying therapies for multiple sclerosis (MS).
    • It emphasizes the importance of early treatment initiation and personalized therapeutic strategies.
    • Decision-making involves evaluating drug benefits and risks alongside patient-specific factors like life and family planning.

    Impact:

    • Aims to guide clinicians in navigating complex therapeutic choices for MS patients.
    • Facilitates informed decision-making by integrating disease characteristics with patient-centered factors.
    • Contributes to optimizing treatment outcomes in multiple sclerosis management.